HLN 📈 Haleon - Overview

Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US4055521003

HLN: Toothpaste, Mouthwash, Vitamins, Supplements, Pain Relievers, Antacids

Haleon plc operates as a prominent player in the consumer healthcare sector, with a vast geographic presence spanning North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. Through its subsidiaries, the company is engaged in the research, development, manufacture, and sale of a diverse range of consumer healthcare products. Its product portfolio encompasses oral health products, including toothpastes, mouthwashes, and denture care products, which are marketed under well-established brands such as Sensodyne, Polident, Parodontax, and Biotene. Additionally, Haleon offers a variety of vitamins, minerals, and supplements under notable brands like Centrum, Emergen-C, and Caltrate, catering to the nutritional needs of its customers.

The company's over-the-counter product lineup is extensive, featuring nasal drops, cold, flu, and allergy relief products under brands like Otrivine, Theraflu, and Flonase, which are designed to provide relief from respiratory issues. Furthermore, Haleon's product portfolio includes anti-inflammatory and pain relief products marketed under Voltaren, Panadol, and Advil brands, as well as antacids and antihistamine products under TUMS, ENO, and Fenistil brands, which are aimed at addressing digestive health and other related issues. This broad range of products underscores the company's commitment to delivering comprehensive healthcare solutions to its customers.

Historically, Haleon plc has its roots dating back to 1715, and it has undergone significant transformations over the years. Formerly known as DRVW 2022 plc, the company changed its name to Haleon plc in February 2022, marking a new chapter in its evolution. Headquartered in Weybridge, the United Kingdom, Haleon plc is listed on the New York Stock Exchange (NYSE) under the ticker symbol HLN, with its common stock classified under the GICS Sub Industry: Biotechnology. The company's web presence can be accessed at https://www.haleon.com, and its ISIN is US4055521003, providing investors and stakeholders with easy access to information about its operations and performance.

Additional Sources for HLN Stock

HLN Stock Overview

Market Cap in USD 43,723m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Biotechnology
IPO / Inception 2022-07-22

HLN Stock Ratings

Growth 5y 63.5%
Fundamental 32.7%
Dividend 39.3%
Rel. Strength Industry 107
Analysts 4.25/5
Fair Price Momentum 9.28 USD
Fair Price DCF 10.09 USD

HLN Dividends

Dividend Yield 12m 1.62%
Yield on Cost 5y 2.16%
Annual Growth 5y 22.87%
Payout Consistency 100.0%

HLN Growth Ratios

Growth Correlation 3m -72.1%
Growth Correlation 12m 83.4%
Growth Correlation 5y 85.3%
CAGR 5y 12.46%
CAGR/Mean DD 5y 1.86
Sharpe Ratio 12m 0.90
Alpha 11.20
Beta 0.25
Volatility 16.32%
Current Volume 5796.1k
Average Volume 20d 7222.2k
What is the price of HLN stocks?
As of December 21, 2024, the stock is trading at USD 9.69 with a total of 5,796,123 shares traded.
Over the past week, the price has changed by -0.72%, over one month by +2.22%, over three months by -7.89% and over the past year by +21.90%.
Is Haleon a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Haleon is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 32.65 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HLN as of December 2024 is 9.28. This means that HLN is currently overvalued and has a potential downside of -4.23%.
Is HLN a buy, sell or hold?
Haleon has received a consensus analysts rating of 4.25. Therefor, it is recommend to buy HLN.
  • Strong Buy: 2
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for HLN stock price target?
According to ValueRays Forecast Model, HLN Haleon will be worth about 10 in December 2025. The stock is currently trading at 9.69. This means that the stock has a potential upside of +3.41%.
Issuer Forecast Upside
Wallstreet Target Price 10.8 11%
Analysts Target Price 9.3 -4.5%
ValueRay Target Price 10 3.4%